Tired of batch variability ruining your research? 🧪

Optimer® binders are chemically synthesised for total consistency across lots. No more re-standardisation, just reproducible data you can trust.

aptamergroup.com/download/311...

Gemini said
Struggling with binder pairs? 🧬

Optimer® ELISA pairs are identified simultaneously to save you time.

See how: aptamergroup.com/aptamer-apta...

We're delighted to announce that our Optimer® technology is included in a newly launched library preparation kit
aptamergroup.com/optimer-tech...

We're hiring for an Oligonucleotide Synthesis Manager. 🧑‍🔬🧬🧪
Join us and bring your aptamer synthesis powers to help deliver the next generation of diagnostics and therapeutics.

aptamergroup.com/careers/synt...

Explore our Optimer Platform!🧬

1 platform. 3 parallel discovery processes. Unlimited solutions with antibody alternatives for your life science needs.

t.co/O0LnJC2nV6

We’ve levelled up! 🥇

🧬 Our ISO 9001 certification now covers synthesis, ensuring top quality across everything from internal development to custom aptamer and oligo synthesis. 🧬💎

Looking for synthesis support? We’ve got you. 🤝

Hear what our customers are experiencing with Optimer technology.

⚡ Superior performance from day one
✅ Ready to use with minimal optimisation
🧬 Outperforming traditional antibodies

Ready to experience the Optimer advantage in your research? Get in touch to learn more.

Technical update from Aptamer Group – Dr David Bunka shares the latest data & innovations. 6pm BST today. Register: turnerpope.com/register/

We're helping customers move away from animal-derived antibodies. 🧬✨

Check out this interview 🎥 from the Danish Society for the Protection of Laboratory Animals, to learn how Optimer is entirely animal-free, from discovery to manufacture. 🐾❌

forsoegsdyrenes-vaern.dk/interview-da...

These two stocks have DOUBLED since I tipped them, reveals our guru The UK has been on a losing streak for too long. But the clouds seem to be lifting and Britons are beginning to win again.

Thrilled to be named a "British global star" in the Mail on Sunday’s Midas column!
Huge thanks to Joanne Hart for spotlighting Aptamer Group, our pharma + @unileveruki.bsky.social partnerships & our cutting-edge work in diagnostics + therapeutics.
Read more 📰: www.thisismoney.co.uk/money/mailpl...

Results of the General Meeting are now available.

To see the results, please head over to our Investor relations reports and presentation page.

aptamergroup.com/investors/re...

The cancer drugs that could lower the risk of Alzheimer’s disease

🧠 New @ucsanfrancisco.bsky.social study shows cancer drugs may help treat Alzheimer’s, backed up by real-world data.
Working with Neuro-Bio, we're developing a diagnostic for Alzheimer's, aiming to unlock value from available therapies to stop this disease.
www.independent.co.uk/bulletin/new...

Additional Work Commissioned By Unilever 21 July, 2025: Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry,

Working with our partners, Unilever, we are carrying out further paid work to support testing and development of Optimer as deodorant ingredients. aptamergroup.com/additional-w...

The circular and information on the general meeting for shareholders, regarding the proposed placing of £2m, is available on our website: polaris.brighterir.com/public/aptam...

We have successfully raised £2M. This will accelerate:
- Licensing discussions
- Manufacturing
- Biomarker discovery service launch
- Animal models for liver fibrosis delivery
- AI/ML integration into Optimer
polaris.brighterir.com/public/aptam...

We've made great progress in the development of the Optimer delivery vehicle targeting liver fibrosis:
🔬 Identification of a novel biomarker targeted by Optimer for liver fibrosis therapies
🧬 Reduction in scar tissue formation in liver fibrosis models
👉 polaris.brighterir.com/public/aptam...

Our new agreement with a global life science leader will see development of Optimer-Fc reagents for new immunohistochemistry reagents, with downstream licensing agreed.
Find out more here: polaris.brighterir.com/public/aptam...

Illumina picks up proteomics developer SomaLogic from Standard BioTools for $425M Illumina is diving deeper into proteomics research with a $425 million plan to acquire SomaLogic, including its protein analysis platforms and certified lab services business. | Illumina is diving dee...

Illumina’s acquisition of SomaLogic is a huge validation of the power and potential of aptamers.

Aptamers offer specificity, scalability, and versatility beyond antibodies. In this $425M deal, aptamers are seen as a driving force in 'omics exploration.
www.fiercebiotech.com/medtech/illu...

We're excited to announce the agreement of the second Optimer development programme with @unileveruki.bsky.social.

We look forward to working together to expand the potential of Optimer applications in personal care.

polaris.brighterir.com/public/aptam...

Join us at this year's #BIO2025!

Our CEO, Arron Tolley, and CFO, Andrew Rapson, will be at this year’s BIO International Convention in Boston. Book a meeting to see how #Optimer can deliver better affinity ligands to support your pipeline.
letspartner.bio.org

Expanding The ADC Toolkit With 4 Critical Optimer® Benefits Expanding the ADC toolkit with the use of next-generation targeting ligands like Optimer could bring increased precision and adaptability, allowing for

ADCs are pushing the boundaries of targeted cancer therapy, but off-target effects, poor tumor penetration, and limited stability are still major hurdles.

That’s where Optimer comes in.

Learn about the four key ways Optimer can enhance your ADC programs: aptamergroup.com/expanding-ad...

If you missed us at #ASGCT2025 last week, you can go to our website to download our poster, ‘Targeted Delivery of siRNA to Activated Hepatic Stellate Cells Using Aptamers: A Novel Approach for Fibrotic Liver Treatment’ which was presented at the conference.
go.aptamergroup.com/ASGCT-Poster

How Can Aptamer Stability Be Improved In Vivo? As the number of aptamers in the clinical pipeline grows, it demonstrates that aptamer stability can be optimised to match the therapeutic strategy. Binders

🎯Optimer delivery vehicles can be tuned to match therapeutic strategy.💊

Whether you need ⏩ rapid delivery and renal filtration or a ⏸️ longer half-life with hepatic elimination, Optimers can be simply engineered to align with your payload and disease.

aptamergroup.com/how-can-apta...

We’re all set up and ready to go at #ASGCT.

Come meet our team at stand 714 to see how #Optimer, oligo-based antibody alternatives, can target gene therapy payloads to specific sites of action in the body or help build better assays for drug discovery and drug development.

Join our team next week at #ASGCT to see how Optimer can help with:
🎯Targeted delivery for your gene therapy
🧪Custom reagents to build better assays
🔍 Identify new biomarkers of disease

Don’t miss our poster
📊 ‘Targeted Delivery of siRNA to Activated Hepatic Stellate Cells Using Aptamers’

Getting the Right Gene Therapy to the Right Tissue As we continue to see sequencing technologies advance and provide a deeper understanding of gene therapy targets along with more precise targeting and delivery options, they will become increasingly e...

Optimer is rethinking gene therapy delivery for new precision medicines

Check out the article in Genetic Engineering & Biotechnology News discussing how Optimer is enabling gene therapy delivery to specific tissues for new precision medicines.

www.genengnews.com/sponsored/ge...

Imatinib Detection by Memristive Biosensors for Therapeutic Drug Monitoring Therapeutic drug monitoring is essential for optimizing the efficacy and safety of targeted anticancer agents like imatinib, a first-line treatment fo…

Congratulations to researchers at EPFL, in collaboration with VitalizeDx, on their latest paper showing the use of our Imatinib Optimer for therapeutic drug monitoring of chemotherapeutic drug regimes as part of a biosensor assay!
www.sciencedirect.com/science/arti...

Meet us at #FoBUSA 📅 Apr 23–24, stand 1244! 🤝 Book time with Arron & Zeesharn + see poster 7 on Optimer® gene silencing in primary fibrotic hepatic stellate cells.

Not all binders are equal. Learn how Optimer® binders are tailored for detection, purification & targeted delivery. Watch now: bit.ly/4bDGFwk

Reproducibility matters. Chemically synthesized aptamers offer the highest batch consistency for robust assays & reliable data. 🔬📊

🔗 aptamergroup.com/aptamers-offer-the-highest-batch-consistency-for-reliable-reproducibility/